FOXO Technologies Stock Price, News & Analysis

FOXO TECHNOLOGIES INC WTS (FOXOW) represents warrants related to FOXO Technologies Inc., a Delaware corporation. Information about FOXO Technologies Inc. in recent SEC filings focuses on corporate governance actions, capital structure changes, preferred stock designations, and acquisition activity. These filings provide context for how the company structures its equity, including common stock, preferred stock, and warrants.

According to multiple Form 8-K filings, FOXO Technologies Inc. has amended its Certificate of Incorporation and various Certificates of Designation for several series of preferred stock. These amendments address matters such as conversion prices, dividend terms, and the number of authorized shares of both Class A Common Stock and Preferred Stock. The company has also used written consents from a majority stockholder to approve certain corporate actions, including increases in authorized share counts and the re-election of directors.

One Form 8-K describes the acquisition of Vector Bio Source Inc. through a Stock Purchase Agreement. In that transaction, the sellers of Vector received cash, shares of Series E Cumulative Redeemable Secured Preferred Stock, and warrants to purchase Class A Common Stock of FOXO Technologies Inc. This illustrates how the company uses a mix of cash, preferred equity, and warrants in its corporate and financing transactions.

Another Form 8-K notes that FOXO Technologies Inc. has a behavioral health subsidiary, Myrtle Recovery Centers, which received recognition from the Rural Health Association of Tennessee at an annual conference awards event. This indicates that, in addition to its capital markets activity, the company has operating subsidiaries in the behavioral health area.

Because the available data is drawn from specific SEC filings, most of the accessible information about FOXO Technologies Inc. and its related warrants concerns legal, capital structure, and transactional details rather than a broad operational profile. Investors reviewing FOXOW may therefore focus on how changes to preferred stock terms, increases in authorized shares, and warrant issuances could affect the overall capitalization of FOXO Technologies Inc.

Capital structure and preferred stock designations

Recent Form 8-K filings describe amendments to the Certificates of Designation for several series of preferred stock, including Series B, Series C, Series D, and Series E. These amendments revise conversion prices, clarify dividend payment schedules, and adjust other rights, privileges, and preferences associated with these securities. The filings state that summaries in the 8-Ks are qualified in their entirety by reference to the full Amended and Restated Certificates of Designation attached as exhibits.

In one filing, FOXO Technologies Inc. reports that the conversion price for certain series of preferred stock is set as the higher of a fixed dollar amount per share or a percentage of the average volume-weighted average price (VWAP) over a specified trading period before a conversion notice is tendered. Another filing clarifies that dividends on a series of preferred stock are paid on a semi-annual basis. These details help define how preferred stock can convert into common stock and how dividends are scheduled.

Authorized share increases and majority stockholder actions

Several 8-K filings describe actions approved by a majority stockholder, Rennova Health, Inc., which is identified as being controlled by the company’s CEO. This majority stockholder has held a significant percentage of the company’s voting rights, as reported in the filings, and has used written consents to approve amendments to the Certificate of Incorporation.

These amendments include increases in the authorized shares of Class A Common Stock and increases in the authorized shares of Preferred Stock. In one instance, the company filed a Certificate of Amendment with the Secretary of State of Delaware to increase authorized common shares, with the filing becoming effective on a specified date. In another instance, the majority stockholder approved further increases in authorized common and preferred shares that may be implemented by the board of directors within a defined time frame, without additional stockholder approval before the amendment is filed.

The filings also describe the re-election of directors to serve until the next annual meeting or until their successors are elected or qualified, as well as the non-binding ratification of the appointment of an independent registered public accounting firm for a fiscal year. These disclosures provide insight into the company’s governance and oversight structures.

Acquisition activity and use of warrants

FOXO Technologies Inc. has reported the completion of an acquisition of Vector Bio Source Inc. through a Stock Purchase Agreement. At closing, the sellers of Vector exchanged their shares for cash, shares of Series E Cumulative Redeemable Secured Preferred Stock, and warrants to purchase Class A Common Stock of FOXO Technologies Inc. The warrants have a stated exercise price per share, and the company attached a form of the warrant agreement as an exhibit to the Form 8-K.

This transaction shows how FOXO Technologies Inc. incorporates preferred equity and warrant instruments into its acquisition and financing structures. The issuance of warrants in connection with the acquisition is relevant context for understanding FOXO TECHNOLOGIES INC WTS (FOXOW), which reflects warrant interests tied to the company’s equity.

Subsidiaries and recognition

In a Regulation FD disclosure on Form 8-K, FOXO Technologies Inc. reports that its behavioral health subsidiary, Myrtle Recovery Centers, received recognition from the Rural Health Association of Tennessee at an annual conference awards luncheon. The company furnished a press release as an exhibit to that filing. The Form 8-K notes that the information under Item 7.01, including the exhibit, is furnished rather than filed for purposes of certain Exchange Act provisions.

This disclosure indicates that FOXO Technologies Inc. has operations through at least one behavioral health subsidiary and that this subsidiary has been acknowledged by a regional health association. The filing also includes standard language about the treatment of furnished information and references to securities law provisions.

Regulatory filings and information statements

Several 8-K filings mention that FOXO Technologies Inc. has filed, or will file, a preliminary Information Statement on Schedule 14C with the U.S. Securities and Exchange Commission. These information statements relate to matters approved by the majority stockholder, such as increases in authorized share capital. The filings state that definitive information statements will be mailed to stockholders of record as of specified record dates and that the approved items will become effective after a set period following mailing.

These references highlight how the company communicates corporate actions that do not require a traditional stockholder meeting but instead proceed by written consent and subsequent information statement. For investors analyzing FOXOW, these processes may be relevant when considering potential dilution, capital structure changes, and governance dynamics.

How FOXOW relates to FOXO Technologies Inc.

Based on the available SEC filings, FOXO Technologies Inc. issues warrants as part of certain transactions, including acquisitions. FOXO TECHNOLOGIES INC WTS (FOXOW) is associated with warrants linked to the company’s equity. While the filings describe specific warrants issued in connection with the acquisition of Vector Bio Source Inc., the broader warrant structure and detailed terms for FOXOW itself are not fully described in the provided excerpts. Investors typically review the relevant warrant agreements and registration statements for complete terms, including exercise price, expiration, and adjustment mechanisms.

Key considerations for investors

The information available for FOXO Technologies Inc. is centered on SEC disclosures about capital structure, preferred stock designations, warrant issuances, acquisition activity, and governance actions. For someone researching FOXOW, these filings are primary sources for understanding how the company manages its equity and how warrants may interact with common and preferred stock. Because the provided data does not include a broad business description or financial performance details, analysis is largely based on the legal and structural information contained in the 8-Ks and related exhibits.